In yesterday’s Wall Street session, Surface Oncology Inc. (NASDAQ:SURF) shares traded at $1.03, up 3.00% from the previous session.
As of this writing, 6 analysts cover Surface Oncology Inc. (NASDAQ:SURF). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $3.00, we find $6.00. Given the previous closing price of $1.00, this indicates a potential upside of 500.0 percent. SURF stock price is now 12.68% away from the 50-day moving average and -31.28% away from the 200-day moving average. The market capitalization of the company currently stands at $63.65M.
There are 0 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $5.40 as their price target over the next twelve months.
With the price target of $17, BTIG Research recently initiated with Buy rating for Surface Oncology Inc. (NASDAQ: SURF). On September 04, 2020, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $11, while ‘Wedbush’ rates the stock as ‘Outperform’.
In other news, ONEILL ALISON, Chief Medical Officer sold 4,463 shares of the company’s stock on Aug 03. The stock was sold for $7,676 at an average price of $1.72. Upon completion of the transaction, the Chief Medical Officer now directly owns 63,728 shares in the company, valued at $65639.84. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 03, Chief Business Officer RATH HENRY C. sold 5,676 shares of the business’s stock. A total of $9,763 was realized by selling the stock at an average price of $1.72. This leaves the insider owning 32,324 shares of the company worth $33293.72. Insiders disposed of 31,176 shares of company stock worth roughly $32111.280000000002 over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SURF stock. A new stake in Surface Oncology Inc. shares was purchased by NIKKO ASSET MANAGEMENT AMERICAS, INC. during the first quarter worth $1,137,000. SUMITOMO MITSUI TRUST HOLDINGS, INC. invested $1,137,000 in shares of SURF during the first quarter. In the first quarter, CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. acquired a new stake in Surface Oncology Inc. valued at approximately $101,000. MAN GROUP PLC acquired a new stake in SURF for approximately $14,000. BALYASNY ASSET MANAGEMENT LLC purchased a new stake in SURF valued at around $11,000 in the second quarter. In total, there are 118 active investors with 53.50% ownership of the company’s stock.
Monday morning saw Surface Oncology Inc. (NASDAQ: SURF) opened at $1.0000. During the past 12 months, Surface Oncology Inc. has had a low of $0.60 and a high of $4.05. As of last week, the company has a debt-to-equity ratio of 0.23, a current ratio of 8.30, and a quick ratio of 8.30. The fifty day moving average price for SURF is $0.9141 and a two-hundred day moving average price translates $1.4989 for the stock.
The latest earnings results from Surface Oncology Inc. (NASDAQ: SURF) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.46, inline with analysts’ expectations of -$0.46. This compares to -$0.44 EPS in the same period last year. For the current quarter, analysts expect SURF to generate $80k in revenue.
Surface Oncology Inc.(SURF) Company Profile
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.